Statistical methods in cardiovascular trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
Hazard ratio
ANCOVA
Cox proportional-hazards model
Non-inferiority trial design
Multiple imputation / missing data
Odds ratio
Log-rank test
t-test
All cardiovascular trials
672 results
- CARAVAGGIOIndependent statistical analysis of Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Cardiac Rehabilitation Peer Mentorship: Complete Statistical AnalysisIndependent statistical analysis of Cardiac Rehabilitation Peer Mentorship: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02204449).
- Cardio-pulmonary Rehabilitation and Sleep Quality: Complete Statistical AnalysisIndependent statistical analysis of Cardio-pulmonary Rehabilitation and Sleep Quality: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04668599).
- Cardiometabolic Effects of Pecans as a Snack: Complete Statistical AnalysisIndependent statistical analysis of Cardiometabolic Effects of Pecans as a Snack: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05071807).
- CARESComplete statistical analysis of the CARES phase 3 trial of febuxostat versus allopurinol in participants with gout and cardiovascular comorbidities, including MACE, cardiovascular death, myocardial infarction, stroke, and survival-analysis methodology.
- Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CARTERIndependent statistical analysis of Circuitry Assessment and Reinforcement Training Effects on Recovery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04290988).
- CARVIVA-HFIndependent statistical analysis of Heart Rate Reduction in Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01178528).
- CASDAF-HDIndependent statistical analysis of Characterising the Stable and Dynamic Left Atrial Substrate in Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Case Managers for CVD Risk Reduction in HIV Clinic: Complete Statistical AnalysisIndependent statistical analysis of Case Managers for CVD Risk Reduction in HIV Clinic: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03839394).
- CassetteIndependent statistical analysis of Correlation of Auscultatory Severity of Aortic Stenosis With Trans Thoracic Echocardiography: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- CASTAn independent statistical analysis of CAST, the phase 3 Cardiac Arrhythmia Suppression Trial, covering its randomized double-masked prevention design, interventions, statistical framework, planned analysis considerations, and limitations of the registry record.
- CASTIndependent statistical analysis of Curosurf and Survanta Treatment(CAST)of RDS in Very Premature Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00767039).
- CASTLE-AFIndependent statistical analysis of CASTLE-AF (NCT00643188), including trial design, endpoints, planned statistical methodology, and interpretation of the randomized catheter ablation study in patients with left ventricular dysfunction and atrial fibrillation.
- CBIndependent statistical analysis of Cutting Balloon Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01205568).
- CC-5013 (Lenalidomide) and Rituximab in Waldenstrom’s Macroglobulinemia: Complete Statistical AnalysisIndependent statistical analysis of CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00142168).
- Cerebellar Transcranial Direct Current Stimulation and Aphasia Treatment: Complete Statistical AnalysisIndependent statistical analysis of Cerebellar Transcranial Direct Current Stimulation and Aphasia Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02901574).
- Cerebral Protection in Transcatheter Aortic Valve Replacement: Complete Statistical AnalysisIndependent statistical analysis of Cerebral Protection in Transcatheter Aortic Valve Replacement: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02214277).
- CES1 Carriers in the PAPI Study: Complete Statistical AnalysisIndependent statistical analysis of CES1 Carriers in the PAPI Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03188705).
- CESARIndependent statistical analysis of CESAR, a prospective cohort of acute cardiology referrals in an ambulatory day-hospital setting, including its study population, endpoint definition, planned proportion analysis, and statistical interpretation.
- CHAMPION 1Independent statistical analysis of A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- CHAMPION 2Independent statistical analysis of A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- CHAMPSIndependent statistical analysis of Connected Health Blood Pressure Monitoring In Stroke and TIA Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02450760).
- CHARISMAIndependent statistical analysis of CHARISMA, a randomized phase 3 trial of clopidogrel in patients with arteriosclerosis, including its design, primary endpoint, planned time-to-event analysis, and statistical interpretation.
- CHARM-AddedIndependent statistical analysis of CHARM-Added, a randomized phase 3 trial evaluating candesartan cilexetil versus placebo in patients with congestive heart failure.
- CHARM-AlternativeIndependent statistical analysis of CHARM-Alternative, a phase 3 randomized trial evaluating candesartan versus placebo in congestive heart failure. Includes trial design, endpoints, planned statistical methods, and interpretation.
- CHARM-PreservedIndependent statistical analysis of CHARM-Preserved, the randomized phase 3 trial evaluating candesartan cilexetil versus placebo in congestive heart failure. Includes trial design, endpoints, statistical methodology, and interpretation.
- Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: Complete Statistical AnalysisIndependent statistical analysis of Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant: primary endpoint results,…
- CHEST ExtensionIndependent statistical analysis of the CHEST Extension trial evaluating the Rapid Rhythm handheld 8-lead ECG device in patients with atrial fibrillation and heart murmurs, including its diagnostic endpoints, study design, planned analysis,…
- CHEST-2Independent statistical analysis of CHEST-2, a phase 3 long-term extension study of riociguat in patients with pulmonary hypertension, including trial design, registered endpoints, safety results, planned statistical interpretation, and methodological context.
- CHIVESIndependent statistical analysis of Designing Food Voucher Programs to Reduce Disparities in Healthy Diets: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02843178).
- Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Chronotropic Incompetence in Patients With HFpEF: Complete Statistical AnalysisIndependent statistical analysis of Chronotropic Incompetence in Patients With HFpEF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02524145).
- CIRTIndependent statistical analysis of Cardiovascular Inflammation Reduction Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01594333).
- CLARITY-TIMI 28Independent statistical analysis and educational interpretation of CLARITY-TIMI 28, a randomized phase 3 trial evaluating clopidogrel as adjunctive reperfusion therapy in acute coronary syndromes.
- CLASP IIDIndependent statistical analysis of CLASP IID, evaluating the Edwards PASCAL System versus the Abbott MitraClip System for mitral regurgitation, including non-inferiority endpoints, trial design, planned statistical methods, and interpretation.
- Cleaner Air for Better Cardiac Biomarkers: Complete Statistical AnalysisIndependent statistical analysis of Cleaner Air for Better Cardiac Biomarkers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05379400).
- CLEARIndependent statistical analysis of Cilostazol After Lower Extremity Arterial Revascularization Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02374957).
- CLEAR OutcomesIndependent statistical analysis of CLEAR Outcomes, the randomized phase 3 trial of bempedoic acid versus placebo in statin-intolerant participants with or at high risk for cardiovascular disease, including MACE, secondary time-to-event endpoints,…
- CLEAR SYNERGYIndependent statistical analysis of CLEAR SYNERGY, a randomized phase 3 factorial trial evaluating colchicine and spironolactone strategies in patients with ST elevation or non-ST elevation myocardial infarction, including its primary endpoints, trial…
- Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants: Complete Statistical AnalysisIndependent statistical analysis of Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy: Complete Statistical AnalysisIndependent statistical analysis of Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00879060).
- Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis: Complete Statistical AnalysisIndependent statistical analysis of Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Clinical Evaluation of the OEC Elite Vascular Mobile Fluoroscopy System: Complete Statistical AnalysisIndependent statistical analysis of Clinical Evaluation of the OEC Elite Vascular Mobile Fluoroscopy System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03096483).
- Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve: Complete Statistical AnalysisIndependent statistical analysis of Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00630916).
- Clinical Study of Lipoic Acid on Ischemic Heart Failure: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study of Lipoic Acid on Ischemic Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03491969).
- Clinical Study to Compare Two Skin Substitute Categories for Their Effectiveness to Treat Diabetic Foot Ulcers: Complete Statistical AnalysisIndependent statistical analysis of Clinical Study to Compare Two Skin Substitute Categories for Their Effectiveness to Treat Diabetic Foot Ulcers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Clinically Indicated Magnetic Resonance Imaging in Patients With Cardiac Devices: Complete Statistical AnalysisIndependent statistical analysis of Clinically Indicated Magnetic Resonance Imaging in Patients With Cardiac Devices: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01130896).
- CLOSEA statistical analysis of the CLOSE phase 3 trial evaluating patent foramen ovale closure or anticoagulants versus antiplatelet therapy to prevent stroke recurrence.